Target Group Inc. (OTCQB: CBDY) announced that its subsidiary, Canary Rx Inc., has fulfilled approximately 665 kgs of craft cannabis worth over $1.9 million wholesale. These sales are attributed to partnerships across Canada facilitated through their Joint Venture, Venn Cannabis. CEO Tony Zarcone emphasized the importance of their partnerships with respected retail brands, highlighting the premium quality of their craft cannabis. The company aims to secure long-term contracts and predictable revenue streams to expand market reach and production capabilities.
Target Group Inc. (OTCQB: CBDY) announced that its subsidiary, Canary Rx Inc., has received a Health Canada sales license. This authorization allows Canary to manufacture and sell cannabis products to provincial distributors and authorized retailers, supporting its consumer packaged goods strategy. The company aims to deliver premium craft cannabis through its Ontario facility and expects to solidify its position in contract-based cultivation over the next 12-18 months. CEO Tony Zarcone emphasized the importance of this licensing milestone for executing their commercial strategy.
Target Group Inc. (CBDY) announced that its subsidiary, Canary Rx Inc., successfully completed its first three wholesale cannabis transactions through its joint venture, Venn Cannabis. This development signals a potential growth trajectory for the company in the Canadian cannabis market. Canary Rx aims to produce craft cannabis at its Simcoe, Ontario facility, enhancing its wholesale operations and establishing partnerships with licensed producers. The company expects these transactions to create significant revenue opportunities and strengthen its market position.